Product logins

Find logins to all Clarivate products below.


Acute Myeloid Leukemia – Epidemiology – Epidemiology Dashboard

Clarivate Epidemiology’s coverage of AML comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the diagnosed incidence and diagnosed prevalence of AML for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the mature markets and Europe, and 10 years for the other countries we cover.

All forecast data are available on Clarivate’s Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods. In addition, we provide a graph depicting the patient flow between or within different disease states for the major mature pharmaceutical markets. These patient-flow diagrams are provided at the regional level but may be requested for any specific country or forecast year.

Clarivate Epidemiology’s AML forecast answers the following questions:

  • How will changes in the levels of exposure to known risk or protective factors affect the number of people living with a diagnosis of AML and the number of new diagnoses of AML?
  • Of all people diagnosed with AML, how many in each country across the major mature pharmaceutical markets are drug-treated?
  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of AML over the forecast period?

In addition to the total number of diagnosed AML incident cases for each forecast year, Clarivate Epidemiology provides at least 10 years of forecast data for the following AML populations:

  • Cytogenetic risk
  • Prevalent cases
  • Drug-treatable populations
  • Drug-treated populations
  • FLT3 mutations

Note: Coverage may vary by country.

Related Market Assessment Reports

Report
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Geographic Focus: China – Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – China In-Depth (China)
The NHL therapy market in China is poised for significant growth over the next decade, driven by the introduction of novel therapies and the continued uptake and label expansion of premium-priced…
Report
Hemophilia A – Landscape & Forecast – Disease Landscape & Forecast (G7)
Roche / Chugai’s Hemlibra has fundamentally transformed the treatment of hemophilia A. For patients with inhibitors who were previously reliant on bypass agent prophylaxis, Hemlibra provides…
Report
Multiple Myeloma – Geographic Focus: China – DIA: China In-Depth – Multiple Myeloma
China’s multiple myeloma therapy market is evolving rapidly, driven by an increasing disease burden and advances in treatment options. Current therapies in China largely mirror global standards;…
Report
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Landscape & Forecast – Disease Landscape & Forecast (G7)
The non-Hodgkin’s lymphoma (NHL) and chronic lymphocytic leukemia (CLL) therapy market is rapidly evolving as novel agents provide alternatives to conventional immunochemotherapy regimens. This…
Report
Inflammatory Myositis – Epidemiology – Mature Markets
Clarivate Epidemiology’s coverage of inflammatory myositis (IM) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States,…